French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and South African biopharmaceutical company Biovac on Thursday announced a partnership to produce inactivated polio vaccines (IPV) in Africa.
This initiative aims to serve over 40 African countries and positions Biovac as the continent's first IPV manufacturer.
Sanofi will continue bulk production, while Biovac will handle final formulation, filling, packaging and distribution of millions of doses to UNICEF for GAVI countries in Africa. This collaboration aligns with the Africa Centers for Disease Control and Prevention's goal of 60% local vaccine production by 2040.
myTomorrows names new director
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
Latigo Biotherapeutics names new chief executive officer
Valneva receives CEPI funding to boost access to world's first chikungunya vaccine
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
INOVIO names new chief commercial officer
Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial
Bavarian Nordic files for chikungunya vaccine approval in Europe
Valneva's chikungunya vaccine IXCHIQ approved by Health Canada
Philippine lawmakers call for probe into secret US propaganda operation
Gavi seeking funding to immunise poorest children
Sanofi partners with Biovac to manufacture polio vaccines in Africa